Scientific objectives
Promoting precision medicine in the treatment of breast (BC), colorectal (CRC), lung (LC) and pancreatic (PC) cancer:
1. Diagnostic biomarkers
Increase prognostic and predictive value.
2. Appraisal of new agents and immunotherapy strategies
Providing a multidisciplinary approach.
Lines of investigation
Early detection
Implementation of molecular tools that allow for early identification of individuals developing a primary tumour or initiating metastatic disease through liquid biopsy.
Microbiota / Microbiome
Characterisation of the microbiome to help improve current methods of diagnosis and disease progression.
Preclinical models
Development of new preclinical platforms to achieve more accurate medicine in BC, LC and CRC, new personalised therapeutic strategies.
